From GlobeNewswire: 2025-01-07 16:49:00

uniQure N.V. has started an underwritten public offering of its ordinary shares and pre-funded warrants, with the option to purchase additional shares. Leerink Partners is the bookrunning manager for the offering. The securities are being offered under a shelf registration statement filed with the SEC. Interested investors can access the preliminary prospectus supplement and prospectus on the SEC’s website. uniQure aims to advance gene therapy treatments for severe medical conditions, including hemophilia B. Forward-looking statements in the press release caution investors about market conditions and potential risks associated with the offering.



Read more at GlobeNewswire: uniQure Announces Proposed Public Offering